About Immucor

Avi Pelossof was named President and CEO for Immucor in January 2018.

With more than two decades of experience in diagnostics, Pelossof joined Immucor from Alere, a global leader in point-of-care diagnostics. Most recently, he served as Global President of Alere’s $750 million infectious disease business unit. Pelossof held a variety of senior positions with Alere since January 2007.

Prior to Alere, Pelossof held leadership positions for Chembio Diagnostics Systems, Inc., a developer, manufacturer and distributor of point-of-care diagnostic tests. He also held various positions focused on Latin America at Citibank, N.A./Citigroup and founded the consulting firm The IMS Group, Inc., which provided strategic market development for companies seeking to expand into Latin America.

Pelossof has a BA in Economics from the University of Michigan and a MBA in Finance and International business from New York University.

Sandy Athenson joined Immucor in March 2012 as Vice President of Commercial Operations of North America.

Mr. Athenson has more than 35 years’ experience in sales, marketing and customer support in North America, South America and Europe. He has a strong track record of building high performing teams and achieving results.

Prior to joining Immucor, Mr. Athenson was Senior Vice President of North America Customer Management for Siemens Healthcare Diagnostics, a division of Siemens AG, which focuses on clinical diagnostic products. In this role, his organization included 2,600 employees in sales, marketing, customer service, technical service, and sales operations. Prior to Siemens, Sandy held various roles with Dade Behring and Baxter.

Mr. Athenson has a Bachelor of Science degree in Finance & Information Systems from the College of Business Administration at Fordham University in New York.

Sukanta Banerjee is an experienced R&D executive with 25 years of experience in IVD assay and system development. His background includes extensive ground level startup and early-stage company management experience. He has a proven track record of successfully bringing multiple PMA and 510(k) approved IVD products from concept into and through clinical development. Sukanta is an inventor on over 50 US and international patents and has more than 25 peer-reviewed scientific publications in the fields of polymer, colloid and analytical chemistry.

Sukanta joined the company in 2008, became VP of R&D in 2018 and CTO in 2019.

Prior to that, he was at BioArray Solutions Ltd. where he was a co-inventor of the BeadChip microarray platform that was acquired and commercialized by Immucor.

Sukanta received his Bachelor and Master’s in Chemical Engineering with honors from India.  He completed his Ph.D. in Chemical Engineering from Tulane University and a post-doctoral fellowship at Purdue University. He also holds a MBA from Rutgers School of Business.

Klaus Gögelein joined Immucor in January 2018 as Vice President Commercial Europe. In October of 2020 he was appointed to the Immucor Executive Leadership Team as Vice President Commercial Operations International responsible for all outside North America Sales.

Mr. Gögelein has 30 years’ experience in sales, marketing and customer support in Europe, North America, Asia and the Middle East. He has a proven track record of building high performing teams and achieving results with direct sales and through distributor channels.

Prior to joining Immucor, Mr. Gögelein was Senior Vice President of Region EME Transfusion business for Fresenius Kabi, a division of Fresenius SE, which focuses on Nutrition, Drugs and Medical Devices. Klaus held various Executive Management positions with changing regional focus within Fresenius, at Mettler Toledo and Berkel.

Klaus has a Bachelor of Business Administration as well as an Executive MBA degree in Executive Management from St. Gallen Management Institute.

Gary Lawson is Immucor’s Vice President, Global Quality Assurance and Regulatory Affairs. He was appointed to this position in September 2021.

Gary joined Immucor in 1999 as a member of the Quality Control team, and rose through a variety of management roles in both technical services and quality. Prior to assuming his current responsibilities, Gary served as Vice President, Quality Systems and Compliance.

In his current role, Gary leads a global organization dedicated to ensuring that Immucor’s quality policy is executed across the enterprise, helping ensure the highest quality products for our customers, and maintaining  compliance with global regulatory requirements.

Prior to joining Immucor, Gary worked in the clinical laboratory, focused in the transfusion service and hematology, and quality control in the medical device space.  He holds a degree in Microbiology and Medical Technology from East Tennessee State University.

Kendall Lioon joined Immucor in 2009 and has served as Immucor’s Vice President and General Counsel since 2019.

Kendall has handled a broad spectrum of legal matters during her Immucor tenure, including a number of acquisitions and strategic transactions.

Before joining Immucor, Kendall was an associate at King & Spalding LLP advising clients on venture capital investments, mergers & acquisitions and private equity transactions.

Kendall earned her law degree from Vanderbilt University and her bachelor’s degree from Dartmouth College.

Christie joined Immucor in 1997 and has worked in a variety of roles in the Marketing organization during her 24 year tenure with the company.   She moved into the Chief Marketing Officer role in late 2020.

In previous positions at Immucor, Christie led both downstream and upstream marketing teams both regionally and globally.  Her greatest marketing passion is working closely with R&D on product development to ensure that the voice of customer needs are captured in new product design.

Christie holds a Biology degree from The University of Richmond.

Dominique Petitgenet was named Vice President and Chief Financial Officer for Immucor in March 2012 and named Chief Operating Officer in June 2017. Previously, Petitgenet served as Chief Financial Officer and Vice President, International Transfusion Diagnostics from May 2014 to December 2015 and as Chief Financial Officer and Vice President, Worldwide Operations from December 2015 to June 2017.

He joined Immucor from Merial, a division of Sanofi, where he served as Chief Financial Officer. Merial (now Boehringer-Ingelheim) is a multibillion-dollar worldwide leader in the animal health industry with sales in 150 countries. Petitgenet held a variety of leadership positions with Merial since 2001.

Previously, Petitgenet held positions with Rhodia, Rhone-Poulenc Group and the Montedison Group.

He earned his master’s degree in finance from Paris Dauphine University.

Peggy Taylor, is the Chief Administrative Officer at Immucor, Inc.  She previously served as Senior Vice President of Human Resources at Biomet from 2007 to 2015 when it sold to Zimmer.  The last year at Biomet, she led the integration efforts in addition to HR.

Mrs. Taylor joined Immucor as Chief Administrative Officer in 2015 and is now responsible for HR, legal and the reference lab business.  Peggy has 20 years Human Resource experience at Abbot (1987-2007) including 7 years as Deputy Vice President Human Resources for Abbot Diagnostics.

Peggy holds a bachelor’s degree from St. Mary’s College, Notre Dame Indiana.